Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025.
1/5 보강
In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed.
APA
Barata P, Hulsey T (2026). Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025.. Oncology and therapy, 14(1), 51-62. https://doi.org/10.1007/s40487-025-00403-w
MLA
Barata P, et al.. "Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025.." Oncology and therapy, vol. 14, no. 1, 2026, pp. 51-62.
PMID
41296192 ↗
Abstract 한글 요약
In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of prostate cancer. This podcast is intended to broaden the reach of complex data and insights from ASCO 2025 to a broader audience, including non-specialists, helping enable better informed treatment decisions between patients and healthcare professionals. The authors begin with a brief summary of the current diagnosis and treatment landscape for patients with prostate cancer, before discussing three topics: personalized therapy for hormone-sensitive prostate cancer; new therapeutics for hormone-resistant prostate cancer; and patient quality of life and supportive care. For hormone-sensitive prostate cancer, biomarker-driven strategies based on genetic and molecular changes in tumor biology and imaging are emerging to help identify which patients may benefit from more targeted treatments. These personalized strategies provide hope to initiate treatment earlier, ultimately preventing disease progression to hormone resistance. For patients who have progressed to difficult-to-treat hormone-resistant prostate cancer, early clinical trials show promise. Novel approaches including radioligands, antibody-drug conjugates, bispecific T cell engagers, and therapy combinations are expanding future treatment options. Finally, mental health screening, educational tools to improve patients' awareness of their disease, and remote health monitoring may help improve the quality of life of patients and their families/caregivers, signposting them to appropriate supportive care. Data presented at ASCO 2025 highlights a shift in the treatment and management of prostate cancer towards a more personalized approach and further amplifies the need to consider individual patient populations. A glossary of abbreviations and terms used in this podcast is provided in the electronic supplementary material. Podcast Audio (MP4 175328 KB).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- The Gut-Prostate Axis: Decoding the Interplay of Environmental Factors, Microbial Metabolites, and Hormonal Regulation in Prostate Cancer Pathogenesis.
- Vitamin C in the Treatment of Colorectal Cancer: Between Hope and Despair.
- Molecular mechanisms and classification of castration-resistant prostate cancer: Insights into androgen receptor, cancer stem cells, and neuroendocrine features.
- Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G.
- A phase II study evaluating pharmacokinetics and dosimetry of Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer.
- polysaccharides inhibit castration-resistant prostate cancer progression possibly via dual modulation of PIK3R1 and PGC-1α: a preclinical evaluation.